Samsung Biologics Says 97.98% Tendered in PolyPeptide Offer
Samsung Biologics is pursuing making PolyPeptide a wholly owned subsidiary after 97.98% of shares were tendered in its public offer.
Related stories
Dala Vind Completes Acquisition of Falu Energi & Vatten Wind Assets
Siljansvik’s Dala Vind acquired the wind assets for 56.5 million kronor.
M impact | MNA | Nov 02, 2026, 10:07 AM UTC
Myriad Uranium Closes $1 Million Los Altares Uranium Project Acquisition
Myriad Uranium acquired a 100% interest in Argentina’s Los Altares Uranium Project for $300,000 in cash and 1,571,268 shares valued at $700,000. The seller received a 2% royalty, h
L impact | MNA | Nov 02, 2026, 10:06 AM UTC
Evonik Board Ends Talks With BASF
Evonik’s board has ended negotiations with BASF.
M impact | MNA | Nov 02, 2026, 10:05 AM UTC
Gamehaus deal valued at $19.60 million, payable in Class A shares
L impact | MNA | Nov 02, 2026, 10:00 AM UTC
Charterhouse Agrees to Sell Vermeg Stake to Advent
Charterhouse Capital Partners has agreed to sell its stake in Vermeg to Advent.
M impact | MNA | Nov 02, 2026, 09:53 AM UTC
Delfin and Lmdv Obtain Citi Financing to Buy Stakes
A Reuters report citing a source says Delfin and Lmdv obtained financing from Citi to acquire stakes.
M impact | MNA | Nov 02, 2026, 09:49 AM UTC